Novartis: Fundamentals still there, momentum more questionable

Nothing too serious or to be worried about but nothing to be excited about either in the Q3 numbers. This quarterly release leaves us with a mixed taste. Short term, RELAX HF2 is key. Without its support and although the current share price is attractive, we would not make Novartis a short-term BUY.

For more information, please contact marketing@bryangarnier.com